| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound does not have a specific reported biological target. As a quinoline derivative, it may interact with various enzymes such as topoisomerases, kinases, or DNA, but the parent carboxylic acid is primarily used as a synthetic intermediate. It is a biochemical compound that could be utilized as a biomaterial or organic/chemical reagent.
|
|---|---|
| ln Vitro |
No specific in vitro biological activity has been reported for Quinoline-6-carboxylic acid itself. It is a synthetic building block; its derivatives may exhibit antibacterial, antimalarial, or anticancer activities. For example, quinoline-6-carboxylic acid has been used in the synthesis of HIV integrase inhibitors and other bioactive molecules.
|
| ln Vivo |
There is no specific in vivo activity reported for this compound. It is not a drug candidate or therapeutic agent, but rather a synthetic intermediate for the preparation of pharmaceuticals. As a building block, any in vivo activity would be associated with the final drug molecule derived from it.
|
| Enzyme Assay |
There is no standard enzyme/receptor binding protocol for this compound. It is typically characterized by analytical methods: HPLC for purity (>98%), NMR for structural confirmation, mass spectrometry for molecular weight confirmation, and melting point determination (approximately 293-295degC). No biological assays are performed on this intermediate.
|
| Cell Assay |
If used in cell culture for preliminary screening, Quinoline-6-carboxylic acid can be dissolved in DMSO (stock 10-100 mM) and diluted to working concentrations (1-100 uM) in culture medium. However, this is not standard practice. The compound is not typically used directly in cell-based experiments, as it is a synthetic intermediate.
|
| Animal Protocol |
There is no standard in vivo animal protocol for this compound. It is not administered to animals for pharmacological studies. For safety assessment, acute toxicity studies in rodents may be performed, but this is not a standard protocol for this synthetic intermediate. General chemical safety protocols for handling aromatic carboxylic acids apply.
|
| ADME/Pharmacokinetics |
PK properties are not applicable for this synthetic intermediate. It has moderate water solubility (approximately 1-5 mg/mL) due to the carboxylic acid group and a logP value of approximately 1.5. It is stable under normal storage conditions. Formulation is typically in DMSO or in aqueous base (e.g., 0.1 M NaOH) for solubility.
|
| Toxicity/Toxicokinetics |
Toxicity of Quinoline-6-carboxylic acid is generally low. As an aromatic carboxylic acid, it may be an irritant to skin, eyes, and mucous membranes. At typical handling concentrations, no significant acute toxicity is expected. Standard laboratory safety precautions (gloves, goggles, lab coat) should be used. Quinoline derivatives may be potential mutagens; handle with care.
|
| Additional Infomation |
Quinoline-6-carboxylic acid is a versatile organic building block for the synthesis of pharmaceuticals, agrochemicals, and materials. The quinoline scaffold is present in many FDA-approved drugs, including antimalarials (chloroquine), antibiotics (fluoroquinolones), and anticancer agents (cabozantinib). This compound is a key intermediate in the preparation of such bioactive molecules and is for research use only.
|
| Molecular Formula |
C10H7NO2
|
|---|---|
| Molecular Weight |
173.17
|
| Exact Mass |
173.047
|
| CAS # |
10349-57-2
|
| PubChem CID |
82571
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
348.7±17.0 °C at 760 mmHg
|
| Melting Point |
293-294 °C
|
| Flash Point |
164.7±20.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.685
|
| LogP |
1.81
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C1C([H])=C([H])C2=C(C([H])=C([H])C([H])=N2)C=1[H])=O
|
| InChi Key |
VXGYRCVTBHVXMZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7NO2/c12-10(13)8-3-4-9-7(6-8)2-1-5-11-9/h1-6H,(H,12,13)
|
| Chemical Name |
quinoline-6-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7747 mL | 28.8734 mL | 57.7467 mL | |
| 5 mM | 1.1549 mL | 5.7747 mL | 11.5493 mL | |
| 10 mM | 0.5775 mL | 2.8873 mL | 5.7747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
